470 related articles for article (PubMed ID: 31018961)
1. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis.
Sabbagh S; Pinal-Fernandez I; Kishi T; Targoff IN; Miller FW; Rider LG; Mammen AL;
Ann Rheum Dis; 2019 Jul; 78(7):988-995. PubMed ID: 31018961
[TBL] [Abstract][Full Text] [Related]
2. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis.
Xing X; Li A; Li C
Respir Med; 2020 Oct; 172():106134. PubMed ID: 32905890
[TBL] [Abstract][Full Text] [Related]
3. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.
Srivastava P; Dwivedi S; Misra R
Rheumatol Int; 2016 Jul; 36(7):935-43. PubMed ID: 27193471
[TBL] [Abstract][Full Text] [Related]
4. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
Xu A; Ye Y; Fu Q; Lian X; Chen S; Guo Q; Lu LJ; Dai M; Lv X; Bao C
Rheumatology (Oxford); 2021 Jul; 60(7):3343-3351. PubMed ID: 33331866
[TBL] [Abstract][Full Text] [Related]
5. Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis.
Vojinovic T; Cavazzana I; Ceruti P; Fredi M; Modina D; Berlendis M; Franceschini F
Clin Rev Allergy Immunol; 2021 Feb; 60(1):87-94. PubMed ID: 33141387
[TBL] [Abstract][Full Text] [Related]
6. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
[TBL] [Abstract][Full Text] [Related]
7. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody.
Marie I; Hatron PY; Dominique S; Cherin P; Mouthon L; Menard JF; Levesque H; Jouen F
Semin Arthritis Rheum; 2012 Jun; 41(6):890-9. PubMed ID: 22078416
[TBL] [Abstract][Full Text] [Related]
8. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
Mamyrova G; Kishi T; Shi M; Targoff IN; Huber AM; Curiel RV; Miller FW; Rider LG;
Rheumatology (Oxford); 2021 Apr; 60(4):1839-1849. PubMed ID: 33140079
[TBL] [Abstract][Full Text] [Related]
9. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.
Shah M; Mamyrova G; Targoff IN; Huber AM; Malley JD; Rice MM; Miller FW; Rider LG;
Medicine (Baltimore); 2013 Jan; 92(1):25-41. PubMed ID: 23263716
[TBL] [Abstract][Full Text] [Related]
10. Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52.
Yamasaki Y; Satoh M; Mizushima M; Okazaki T; Nagafuchi H; Ooka S; Shibata T; Nakano H; Ogawa H; Azuma K; Maeda A; Tonooka K; Ito H; Takakuwa Y; Inoue M; Mitomi H; Kiyokawa T; Tsuchida K; Matsushita H; Mikage H; Murakami Y; Chan JY; Ozaki S; Yamada H
Mod Rheumatol; 2016; 26(3):403-9. PubMed ID: 26344678
[TBL] [Abstract][Full Text] [Related]
11. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].
Xie MM; Zou RY; Li Y; Liu Y; Chen LL; Liu XQ; Zhao Q; Ding JJ; Chen ZY; Cai HR
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):765-770. PubMed ID: 31594111
[No Abstract] [Full Text] [Related]
12. Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis.
Temmoku J; Sato S; Fujita Y; Asano T; Suzuki E; Kanno T; Furuya MY; Matsuoka N; Kobayashi H; Watanabe H; Koga T; Shimizu T; Kawakami A; Migita K
Medicine (Baltimore); 2019 May; 98(20):e15578. PubMed ID: 31096460
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.
Bauhammer J; Blank N; Max R; Lorenz HM; Wagner U; Krause D; Fiehn C
J Rheumatol; 2016 Aug; 43(8):1566-74. PubMed ID: 27252419
[TBL] [Abstract][Full Text] [Related]
15. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
Chen F; Li S; Wang T; Shi J; Wang G
Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
[TBL] [Abstract][Full Text] [Related]
16. Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody.
Sclafani A; D'Silva KM; Little BP; Miloslavsky EM; Locascio JJ; Sharma A; Montesi SB
Respir Res; 2019 Nov; 20(1):256. PubMed ID: 31718649
[TBL] [Abstract][Full Text] [Related]
17. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature.
Labirua-Iturburu A; Selva-O'Callaghan A; Vincze M; Dankó K; Vencovsky J; Fisher B; Charles P; Dastmalchi M; Lundberg IE
Medicine (Baltimore); 2012 Jul; 91(4):206-211. PubMed ID: 22732951
[TBL] [Abstract][Full Text] [Related]
18. Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease.
Gui X; Shenyun S; Ding H; Wang R; Tong J; Yu M; Zhao T; Ma M; Ding J; Xin X; Qiu Y; Qiu X; Zhang Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
Rheumatology (Oxford); 2022 Nov; 61(11):4570-4578. PubMed ID: 35148366
[TBL] [Abstract][Full Text] [Related]
19. Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies.
Shi J; Li S; Yang H; Zhang Y; Peng Q; Lu X; Wang G
J Rheumatol; 2017 Jul; 44(7):1051-1057. PubMed ID: 28461650
[TBL] [Abstract][Full Text] [Related]
20. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies.
Frank MB; McCubbin V; Trieu E; Wu Y; Isenberg DA; Targoff IN
J Autoimmun; 1999 Mar; 12(2):137-42. PubMed ID: 10047434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
